Fisher Asset Management
BCRX icon

Fisher Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Fisher Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26M Sell
2,604,027
-129,226
-5% -$1.17M 0.01% 315
2026
Q1 		$26M Buy
2,733,253
+265,686
+11% +$2.06M 0.01% 302
2025
Q4 		$19.2M Sell
2,467,567
-165,129
-6% -$1.19M 0.01% 327
2025
Q3 		$20M Sell
2,632,696
-149,793
-5% -$1.25M 0.01% 322
2025
Q2 		$24.9M Sell
2,782,489
-269,648
-9% -$2.51M 0.01% 291
2025
Q1 		$22.9M Sell
3,052,137
-130,480
-4% -$1.05M 0.01% 309
2024
Q4 		$23.9M Sell
3,182,617
-155,445
-5% -$1.18M 0.01% 326
2024
Q3 		$25.4M Buy
3,338,062
+481,359
+17% +$3.66M 0.01% 311
2024
Q2 		$17.7M Sell
2,856,703
-27,916
-1% -$154K 0.01% 353
2024
Q1 		$14.7M Buy
2,884,619
+50
+0% +$281 0.01% 370
2023
Q4 		$17.3M Sell
2,884,569
-300,630
-9% -$1.74M 0.01% 346
2023
Q3 		$22.6M Sell
3,185,199
-1,139,354
-26% -$8.19M 0.01% 335
2023
Q2 		$30.4M Buy
4,324,553
+31,157
+0.7% +$250K 0.02% 318
2023
Q1 		$35.8M Sell
4,293,396
-137,718
-3% -$1.33M 0.02% 288
2022
Q4 		$50.9M Sell
4,431,114
-732,731
-14% -$9.14M 0.03% 240
2022
Q3 		$65.1M Sell
5,163,845
-52,984
-1% -$682K 0.05% 213
2022
Q2 		$55.2M Buy
5,216,829
+1,230,006
+31% +$12.7M 0.04% 213
2022
Q1 		$64.8M Sell
3,986,823
-110,229
-3% -$1.77M 0.04% 215
2021
Q4 		$56.7M Buy
4,097,052
+1,091,430
+36% +$14.4M 0.03% 233
2021
Q3 		$43.2M Buy
3,005,622
+994,391
+49% +$15.7M 0.03% 247
2021
Q2 		$31.8M Buy
+2,011,231
New +$27.3M 0.02% 276

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Fisher Asset Management's BCRX Position: Q2 2026 in Review

Fisher Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 4.7% in Q2 2026, selling an estimated $1.17M and leaving 2,604,027 shares worth $26M. The position accounts for 0.01% of the portfolio, ranked #315.

Fisher Asset Management first reported a position in BCRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $65.1M in Q3 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Fisher Asset Management held 2,604,027 shares of BioCryst Pharmaceuticals worth $26M as of Q2 2026.
  • Fisher Asset Management sold 129,226 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
  • BioCryst Pharmaceuticals made up 0.01% of Fisher Asset Management's portfolio in Q2 2026, its #315 holding.
  • Fisher Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Fisher Asset Management's BioCryst Pharmaceuticals position peaked at $65.1M in Q3 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.